Eximore
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
About
Eximore Ltd is a biopharmaceutical company focused on the development, and commercialization of our innovative proprietary "pack and release" punctal plug technology therapy for diseases of the eye. Eximore is positioned to become a central player in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current eye drops standard of care by developing a non-invasive, sustained-release alternative. With a focus on advancing our Glaucoma and Dry Eye products through to Phase 2 clinical trials, our goal is to overcome the issues of patient adherence and compliance by providing means of more consistent and reliable drug dosing for better patient outcomes. Teams look it up for Life Sciences, Biopharmaceutical, Biotech.
Frequently asked
What does Eximore do?
Eximore is a Life Sciences company that offers Platform. Teams look it up for Biopharmaceutical, Biotech, MedTech. It is based in Tel Aviv, Israel and was founded in 2014. Public records show about 7 people and $10M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Eximore raised?
Eximore has raised a total of $10M in funding. The most recent round on record is Series A.
Where is Eximore headquartered?
Eximore is headquartered in Tel Aviv, Israel.
When was Eximore founded?
Eximore was founded in 2014.
What industry does Eximore operate in?
Eximore operates in Life Sciences, Biopharmaceutical, Biotech, MedTech, Drug Discovery.
How many employees does Eximore have?
Eximore has approximately 7 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.